RT Journal Article
SR Electronic
T1 A strategy for finding people infected with SARS-CoV-2: optimizing pooled testing at low prevalence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.02.20087924
DO 10.1101/2020.05.02.20087924
A1 Mutesa, Leon
A1 Ndishimye, Pacifique
A1 Butera, Yvan
A1 Souopgui, Jacob
A1 Uwineza, Annette
A1 Rutayisire, Robert
A1 Musoni, Emile
A1 Rujeni, Nadine
A1 Nyatanyi, Thierry
A1 Ntagwabira, Edouard
A1 Semakula, Muhammed
A1 Musanabaganwa, Clarisse
A1 Nyamwasa, Daniel
A1 Ndashimye, Maurice
A1 Ujeneza, Eva
A1 Mwikarago, Ivan Emile
A1 Muvunyi, Claude Mambo
A1 Mazarati, Jean Baptiste
A1 Nsanzimana, Sabin
A1 Turok, Neil
A1 Ndifon, Wilfred
YR 2020
UL http://medrxiv.org/content/early/2020/08/03/2020.05.02.20087924.abstract
AB Suppressing SARS-CoV-2 will likely require the rapid identification and isolation of infected individuals, on an ongoing basis. RT-PCR (reverse transcription polymerase chain reaction) tests are accurate but costly, making regular testing of every individual expensive. The costs are a challenge for all countries and particularly for developing countries. Cost reductions can be achieved by pooling (or combining) subsamples and testing them in groups. We propose an algorithm for pooling subsamples based on the geometry of a hypercube that, at low prevalence, uniquely identifies infected individuals in a small number of tests. We discuss the optimal group size and explain why, given the highly infectious nature of the disease, largely parallel searches are preferred. We report proof of concept experiments in which a positive subsample was detected even when diluted a hundred-fold with negative subsamples. Using these methods, the costs of mass testing could be reduced by a large factor. If infected individuals are quickly and effectively quarantined, the prevalence will fall and so will the cost of regular, mass testing. Such a strategy provides a possible pathway to the longterm elimination of SARS-CoV-2. Field trials of our approach are now under way in Rwanda.Competing Interest StatementThe authors have declared no competing interest.Funding StatementResearch at AIMS is supported in part by the Carnegie Corporation of New York and by the Government of Canada through the International Development Research Centre and Global Affairs Canada. Research at Perimeter Institute is supported in part by the Government of Canada through the Department of Innovation, Science and Economic Development Canada and by the Province of Ontario through the Ministry of Colleges and Universities. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Rwanda National Ethics CommitteeAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData presented in Appendix on Methods and Supplementary Information